North America Breast Cancer Screening Tests Market Industry: Market Size & Forecast 2026

The North America Breast Cancer Screening Tests Market comprises diagnostic technologies and procedures used to detect breast cancer in asymptomatic and at-risk populations. As of 2025, the market is valued at approximately $2.71 billion, with continued expansion expected as healthcare providers prioritize early detection strategies that improve patient outcomes and reduce treatment costs.

• •Market valued at approximately $2.71 billion in 2025 across North America
• •Growth projected at 8.1% compound annual rate through the early 2030s
• •Encompasses mammography, ultrasound, MRI, biopsy tools, and blood/genomic tests

Rising prevalence of breast cancer, particularly among aging populations, remains the primary catalyst for market expansion across the United States and Canada. Technological innovations in digital and 3D mammography, alongside emerging liquid biopsy and AI-assisted diagnostic tools, are improving screening accuracy and driving adoption in clinical settings.

• •Increasing breast cancer incidence rates and aging demographics in North America
• •Advancements in digital mammography, tomosynthesis, and AI-assisted diagnostics
• •Growing emphasis on routine screening programs and women's health awareness initiatives

The market is segmented by screening type, including imaging-based tests such as mammography and MRI, biopsy-based procedures, and molecular or blood-based diagnostic tests. Mammography constitutes the largest segment, while genomic and blood-based tests represent the fastest-growing categories. The United States dominates the North American market due to advanced healthcare infrastructure, higher screening penetration, and favorable reimbursement policies.

• •Mammography holds the largest market share, with digital and 3D tomosynthesis systems leading adoption
• •U.S. market leadership driven by widespread insurance coverage and national screening guidelines
• •Canada contributes a smaller but growing share, supported by publicly funded screening programs

What are the recent trends and outlook?

The market is moving toward personalized screening approaches, with increasing integration of artificial intelligence to improve lesion detection and reduce false positives. Personalized medicine, including genomic risk assessment and biomarker-based tests, is expected to gain prominence. Over the forecast period, the market is anticipated to reach significantly higher valuations, supported by R&D investments, regulatory approvals for innovative screening modalities, and expanding access to screening services.

• •AI and machine learning integration into imaging analysis to enhance diagnostic accuracy
• •Growing adoption of liquid biopsy and multi-cancer early detection blood tests
• •Market expected to sustain 8%+ CAGR through 2031, with emerging technologies driving future growth